
Department of Brain Health News
The UNLV Department of Brain Health will advance research, education, and practice to benefit brain health and the care and treatment of people with brain disorders across the life span. Our faculty specialize in several areas that range from basic and clinical research in neurodegenerative disease, neuropsychology, and occupational therapy.
Current Brain Health News

Groundbreaking discovery was the norm for Rebel researchers in 2022. Here's a selection of our favorite news-making UNLV research highlights from the year.

A collection of news stories highlighting research wins, expert insights, and academic achievement.

UNLV expert Dr. Jeffrey Cummings explains how a new lab expands UNLV's neuroscience research capabilities.

A collection of news stories highlighting the experts and events at UNLV.

Joint Center for Neurodegeneration and Translational Neuroscience earns continuation funding to support regional research, infrastructure, and career development.

A yearlong collection of headlines featuring innovative ideas, discoveries, and partnerships to move Southern Nevada forward.
Brain Health In The News
Predicting when new drugs come to market in the United States has never been an exact science, and it has become even harder since the start of the COVID-19 pandemic, experts told UPI. But some drugs on the horizon have the potential to make a major impact.
AB Science is initiating a Phase 3 trial to evaluate the safety and efficacy of its candidate therapy masitinib in patients with mild to moderate Alzheimer’s disease.
Biopharmaceutical company Axsome Therapeutics Inc. (AXSM:NASDAQ), which is focused on developing new medicines for use in the treatment of central nervous system (CNS) disorders, today announced that "AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer's Disease Agitation) Phase 3 trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer's disease, as compared to placebo."
Newly announced findings from the phase 3 ACCORD trial (NCT04797715) showed that AXS-05 (Axsome Therapeutics), a novel, investigational n-methyl-D-aspartate (NMDA) receptor antagonist, met its primary end point of statistically significant delay in time to relapse and preventing relapse of agitation in patients with Alzheimer disease (AD) agitation.1
Alzheimer’s disease is a progressive neurological disorder that leads to brain atrophy and death of its cells. It is the most common cause of dementia. It leads to a persistent decrease in the ability to think, and in behavioral and social skills; This limits a person’s ability to live independently.

Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did.
Brain Health Experts


